利特昔替尼治疗斑秃在中国获批上市及作用功效简介

Introduction: Litexitinib is an innovative drug developed by Pfizer. It belongs to the irreversible inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase (TEC) kinase family expressed in hepatocellular carcinoma. The trade name is LITFULO. This article mainly talks about the time on the market of Litexitinib, medication guidelines, efficacy, and adverse reaction management.

Time to market

Ritexitinib was approved in the United States on June 23, 2023. It is mainly used to treat severe alopecia areata in adults and adolescents aged 12 years and above. On October 19, 2023, China’s National Medical Products Administration (NMPA) approved the marketing application for ritexitinib. Clinical trial data for ritexitinib show that it promotes hair regeneration on the scalp and also has positive effects on eyebrow and eyelash regeneration. The launch time of drugs may vary depending on region, regulatory approval and other factors. If you need more specific launch time information, it is recommended to consult your local pharmacy or medical institution.

Medication Guide

The recommended dose of ritexitinib is 50 mg per day, taken once a day, either alone or with food. However, you need to swallow the capsule whole when taking it. Do not break it or crush it to avoid affecting the efficacy of the medicine. If you accidentally miss a pill during taking, you should replenish it as soon as possible. However, if the next dose is less than 8 hours away, you should skip the missed dose and resume dosing at the regularly scheduled time.

Effects

1. Suppress immune response: Ritexitinib inhibits the overreaction of the immune system by inhibiting Janus kinase 3 (JAK3) and the tyrosine kinase (TEC) kinase family expressed in hepatocellular carcinoma, blocking gamma common cytokine signaling and reducing the cytolytic activity of NK and CD8+ cells.

2. Promote hair growth: Ritexitinib can regulate cell signaling pathways, help stimulate new hair growth, and improve the hairline of patients with alopecia areata.

3. Reduce inflammatory reaction: This drug also has the effect of reducing inflammatory reaction and helps improve the health of the scalp.

4. Treatment of vitiligo: Ritexitinib is also being studied for the treatment of patients with non-segmental vitiligo. It may treat vitiligo by suppressing the immune system's attack on the skin.

5. Treatment of ulcerative colitis and Crohn's disease: In addition to alopecia areata, ritexitinib is also being studied for the treatment of other immune-mediated inflammatory diseases, such as ulcerative colitis and Crohn's disease.

Adverse reaction management

Possible adverse reactions include infection, severe infection, herpes zoster, malignant tumors, thromboembolic events, urticaria, lowered lymphocyte count, lowered platelet count, etc. When using this drug, you must strictly follow the doctor's instructions and pay attention to observe the body's reaction. If you have any discomfort or abnormality, you should seek medical treatment in time.

While it has shown positive results in treating alopecia areata, it is not suitable for all patients. Before use, a comprehensive physical examination and evaluation should be performed to ensure that the patient's physical condition is suitable for the use of this drug. It is recommended that patients take medication as directed by their doctor and receive symptomatic treatment.